Business
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
PALO ALTO, Calif., April 30, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and liquid offerings of the Guardant Infinity™ platfor
About this update from Nuvalent, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1128,"height":231,"url":"https://media.zenfs.com/en/business-wire.com/1ed7c6a0982d8a5720bc6d12c4813863"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RC9x04du_UmMkVsLxYmdYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5Nw--/https://media.zenfs.com/en/business-wire.com/1ed7c6a0982d8a5720bc6d12c4813863","width":960,"height":197},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_AsIg.nDfBEXgUuTmfkFWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEzMQ--/https://media.zenfs.com/en/business-wire.com/1ed7c6a0982d8a5720bc6d12c4813863","width":640,"height":131},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lox4z2iat9M2KdOH.EapGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNTY7aD00NjI-/https://media.zenfs.com/en/business-wire.com/1ed7c6a0982d8a5720bc6d12c4813863","width":1128,"height":231}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Multi-year global collaboration will leverage Guardant’s tissue and liquid biopsy portfolio to support clinical development and companion diagnostic strategies","length":159,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":159,"olType":false},{"type":"text","content":"PALO ALTO, Calif., April 30, 2026--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and liquid offerings of the Guardant Infinity™ platform.","length":519,"tagName":"p"},{"type":"text","content":"The collaboration reflects the growing importance of precision diagnostics in oncology drug development, where biomarker-driven approaches are increasingly essential for identifying appropriate patient populations, improving trial efficiency, and supporting regulatory approvals.","length":279,"tagName":"p"},{"type":"text","content":"As key components of the collaboration, Guardant Health and Nuvalent plan to:","length":77,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Utilize Guardant’s p...